Background The global Phase III LUX-Lung 8 trial (ClinicalTrials. gov: NCT1523587)
identified significant improvements in progression-free survival (PFS), overall survival (OS) …

Background LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib
and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma …

Background: Primary LL8 data showed significantly improved PFS and OS with afatinib
compared with erlotinib as second-line treatment in pts with lung SCC, leading to the …

Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …

Lung cancer is the leading cause of cancer death in China, and approximately one third of
these cancers are squamous cell carcinoma (SqCC) of the lung. Ethnic diversity and country …

Aim: A is an irreversible ErbB family blocker that has shown promising clinical activity in pts
with SCC of the head/neck and lung. Here, we report results of LL8, a phase III trial that …

Background Patients with advanced squamous cell carcinoma (SCC) of the lung have
limited treatment options. Although treatment with the EGFR tyrosine kinase inhibitor …

8002 Background: Treatment options for pts with advanced SCC of the lung progressing
after platinum-based chemotherapy are limited. Overexpression of EGFR, ErbB receptors …

Background: In LUX-Lung 8, afatinib (A; 40mg/day) significantly improved OS (median 7.9 vs
6.8 months, p= 0.008) and PFS (2.6 vs 1.9 months, p= 0.010) versus erlotinib (E; 150mg/day) …

Compared to adenocarcinoma, fewer effective treatment options are available for advanced
or metastatic squamous cell carcinoma (SCC) of the lung. Afatinib is an orally administered …